About City of Hope
City of Hope is an independent biomedical research and treatment organization for cancer, diabetes and other life-threatening diseases.
Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy. City of Hope’s translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin, monoclonal antibodies and numerous breakthrough cancer drugs are based on technology developed at the institution. AccessHope™, a subsidiary launched in 2019 serves employers and their health care partners by providing access to City of Hope’s specialized cancer expertise.
A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope is ranked among the nation’s “Best Hospitals” in cancer by U.S. News & World Report and received Magnet Recognition from the American Nurses Credentialing Center. Its main campus is located near Los Angeles, with additional locations throughout Southern California and in Arizona.
City of Hope’s commitment to Diversity, Equity and Inclusion
We believe diversity, equity and inclusion is key in serving our mission to provide compassionate patient care, drive innovative discovery, and advance vital education focused on eliminating cancer and diabetes in all of our communities. Our commitment to Diversity, Equity and Inclusion ensures we bring the full range of skills, perspectives, cultural backgrounds and experiences to our work -- and that our teams align with the people we serve in order to build trust and understanding. We are dedicated to fostering a community that embraces diversity - in ideas, backgrounds and perspectives; this is reflected in our work and represented in our people.
We currently have multiple Postdoctoral Fellowship positions within the multidisciplinary research team headed by Dr. Ajay Goel, Professor and Chair, Department of Molecular Diagnostics and Experimental Therapeutics and Associate Director of Basic Sciences, City of Hope Comprehensive Cancer. Our multidisciplinary research group comprises of basic biologists, gastroenterologists, surgeons, oncologists and bioinformaticians, undertaking a number of collaborative projects involving large international consortia.
Our research is focused on translational research as it relates to genomic and epigenomic characterization of various gastrointestinal cancers (GI) including colorectal, pancreatic and gastric cancers, and some of the key research topics include: 1) Development of circulating DNA/RNA-based liquid biopsy biomarkers for cancer diagnosis, prognosis and predictive response to various therapies. 2) Study the epigenetic basis of GI cancers (e.g. aberrant DNA methylation, histone modifications and non-coding RNAs. 3) The genetic basis of early-onset and familial/hereditary colorectal cancers. 4) The role of tumor microenvironment, stem cells, immune regulation and identification of novel targeted therapies. 5) The role of extracellular vesicles/exosomes as in cancer pathogenesis and their role as disease biomarkers. Our group performs cutting-edge research in GI oncology, is very productive and publishes in high-impact journals such as Gastroenterology, JNCI, Clinical Cancer Research, Nature Communications, Annals of Surgery etc.
Key Responsibilities include:
Basic education, experience and skills required for consideration:
City of Hope is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, religion, color, national origin, sex, sexual orientation, gender identity, age, status as a protected veteran, or status as a qualified individual with disability.